Imfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy…
Shionogi, Partners Join to Boost Antimicrobial Stewardship in Kenya
Shionogi Forms Comprehensive Partnership to Strengthen Antimicrobial Stewardship in Kenya Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; “Shionogi”) is pleased to announce that it has signed a comprehensive partnership…
GLISTEN Phase III: Linerixibat Significantly Eases Itch in PBC
GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat,…
Merck and Kansas Announce $895M Investment in De Soto Facilities
Merck Animal Health and State of Kansas Announce $895 Million Investment in De Soto Manufacturing and R&D Facilities Merck Animal Health launches its largest economic development project to date Rahway,…
Johnson & Johnson Increases Global Efforts to Champion Nurses
Johnson & Johnson Expands Global Commitment to Strengthen Nursing Workforce and Improve Healthcare Access Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and…
Lilly Announces Executive Leadership Changes
Eli Lilly Announces Executive Leadership Changes to Propel Future Growth Eli Lilly and Company (NYSE: LLY) today announced a series of executive leadership transitions designed to strengthen its ability to…
Teva to Host Innovation and Strategy Day on May 29 in New York City
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) stands as a unique global biopharmaceutical leader, delivering a wide range of medicines to patients around the world. With a legacy spanning…
Otsuka and Keio Partner on Psychedelics Research for Social Implementation in Japan
Otsuka Pharmaceutical Signs Research Agreement with Keio University to Advance Psychedelic Treatment Infrastructure in Japan Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that it has signed a non-clinical (basic research)…
Argenx Announces Q1 2025 Financial Results and Business Update
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, today announced its financial results for the first quarter…
Takeda Reports FY2024 Results & FY2025 Growth Outlook
Strong FY2024 Performance and Strategic Outlook for FY2025 The company reported core revenue growth of 7.4% at actual exchange rates (AER) and 2.8% at constant exchange rates (CER) for fiscal…
Final Phase 3 MYR301 Data: Longer Bulevirtide Use Sustains Undetectability Post-Treatment
90% of Adults with Chronic Hepatitis Delta Who Cleared Virus on Bulevirtide Stayed Clear Nearly 2 Years After Stopping Treatment Gilead Sciences, Inc. (Nasdaq: GILD) today announced final results from…
New EASL 2025 Data: Gilead’s Livdelzi® (Seladelpar) Effective and Safe Regardless of Prior Treatments
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment…